Racial/Ethnic Differences in Concerns About Current and Future Medications Among Patients With Type 2 Diabetes

Simple item page
dc.contributor.authorHuang, E. S.
dc.contributor.authorBrown, S. E.S.
dc.contributor.authorThakur, N.
dc.contributor.authorCarlisle, L.
dc.contributor.authorFoley, E.
dc.contributor.authorEwigman, B.
dc.contributor.authorMeltzer, D. O.
dc.date.accessioned2019-08-14T15:04:46Z
dc.date.available2019-08-14T15:04:46Z
dc.date.issued2008
dc.description.abstractOBJECTIVE—To evaluate ethnic differences in medication concerns (e.g., side effects and costs) that may contribute to ethnic differences in the adoption of and adherence to type 2 diabetes treatments.RESEARCH DESIGN AND METHODS—We conducted face-to-face interviews from May 2004 to May 2006 with type 2 diabetic patients ≥18 years of age (N = 676; 25% Latino, 34% non-Hispanic Caucasian, and 41% non-Hispanic African American) attending Chicago-area clinics. Primary outcomes of interest were concerns regarding medications and willingness to take additional medications.RESULTS—Latinos and African Americans had higher A1C levels than Caucasians (7.69 and 7.54% vs. 7.18%, respectively; P < 0.01). Latinos and African Americans were more likely than Caucasians to worry about drug side effects (66 and 49% vs. 39%, respectively) and medication dependency (65 and 52% vs. 39%, respectively; both P < 0.01). Ethnic minorities were also more likely to report reluctance to adding medications to their regimen (Latino 12%, African American 18%, and Caucasian 7%; P < 0.01). In analyses adjusted for demographics, income, education, and diabetes duration, current report of pain/discomfort with pills (odds ratio 2.43 [95% CI 1.39–4.27]), concern regarding disruption of daily routine (1.97 [1.14–3.42]), and African American ethnicity (2.48 [1.32–4.69]) emerged as major predictors of expressed reluctance to adding medications.CONCLUSIONS—Latinos and African Americans had significantly more concerns regarding the quality-of-life effects of diabetes-related medications than Caucasians. Whether these medication concerns contribute significantly to differences in treatment adoption and disparities in care deserves further exploration.
dc.description.urihttp://dx.doi.org/10.2337/dc08-1307
dc.identifierhttps://doi.org/10.13016/d1ho-lera
dc.identifier.citationHuang, E. S. and Brown, S. E.S. and Thakur, N. and Carlisle, L. and Foley, E. and Ewigman, B. and Meltzer, D. O. (2008) Racial/Ethnic Differences in Concerns About Current and Future Medications Among Patients With Type 2 Diabetes. Diabetes Care, 32 (2). pp. 311-316.
dc.identifier.issn0149-5992
dc.identifier.otherEprint ID 3168
dc.identifier.urihttp://hdl.handle.net/1903/23776
dc.subjectDisparities
dc.subjectPharmacotherapy
dc.subjectDiabetes
dc.subjectstudies
dc.titleRacial/Ethnic Differences in Concerns About Current and Future Medications Among Patients With Type 2 Diabetes
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
311.pdf
Size:
82.24 KB
Format:
Adobe Portable Document Format
Download

Collections

Minority Health and Health Equity Archive